Combination ACEI and ARB therapy: Additional benefit in renoprotection?

Current Opinion in Nephrology and Hypertension

Volumn 11, Issue 4, 2002, Pages 377-381

  Taal, Maarten W ^a   Brenner, Barry M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Chronic renal disease; Hypertension; Proteinuria; Renoprotection

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GROWTH FACTOR; LISINOPRIL; LOSARTAN; RENIN; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN; ANGIOTENSIN RECEPTOR;

ANTIHYPERTENSIVE ACTIVITY; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; TRANSGENIC MOUSE; VERTIGO; ANIMAL; CELL PROTECTION; CHRONIC DISEASE; DRUG ANTAGONISM; DRUG COMBINATION; KIDNEY DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMAL; CHRONIC DISEASE; CYTOPROTECTION; DRUG THERAPY, COMBINATION; HUMAN; KIDNEY DISEASES; RECEPTORS, ANGIOTENSIN; ANIMALS; HUMANS;

EID: 0036019479     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200207000-00001     Document Type: Review

References (37)

1. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
2. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
3. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
4. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
5. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
6. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
7. Serine protease angiotensin II systems
8. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
9. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure
10. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies
11. The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity
12. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP
13. Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats
14. The effects of the combination of valsartan, an angiotensin II antagonist, plus benazepril, an ACEI, on renal function in the rat remnant kidney model
15. Combining ACE inhibition and angiotensin II blocking stop renal disease in experimental membranous nephropathy
16. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat
17. Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats
18. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation
19. Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats
20. Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade
21. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients
22. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: A clinical experience trial
23. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure
24. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
25. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension
26. 1 receptor antagonists: Is two better than one?
27. Antiproteinuric effect of losartan in patients with chronic renal diseases
28. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy
29. Effects on blood pressure and renal function of adding an angiotensin receptor antagonist (candesartan 8 mg) to an ACE inhibitor in normotensive patients with renal disease
30. Continuing fall in proteinuria after 6-9 months of combined ACEI and ARA with disappearance of proteinuria of 6-21 years duration in 5 patients
31. Safety of the combination of valsartan and benazepril in patients with chronic renal disease
32. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
33. Dual blockade of the renin-angiotensin system in type 1 diabetic patients with diabetic nephropathy
34. Dual blockade of the renin-angiotensin system in diabetic nephropathy
35. Add-on angiotensin receptor blockade with maximized ACE inhibition
36. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels
37. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?